P atients with reduced estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m 2 have been excluded from randomized controlled trials of non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation (AF), 1, 2 and the efficacy of warfarin specifically in patients with AF and reduced eGFR has never been established from randomized controlled trials. Furthermore, observational studies have led to doubts about the use of warfarin in this population. 3, 4 Only few observational studies have reported eGFR in AF cohorts, and these have generally focused on either the risk of stroke associated with reduced renal function without anticoagulation 5 or the risk of bleeding associated with reduced renal function while on anticoagulation. 3 Data on the risks associated with mildly reduced renal function are sparse. We have previously studied the risk associated with coexisting chronic kidney disease and AF and the risks and benefits of anticoagulation in these patients, 6 ,7 but detailed levels of renal function based on creatinine measurements have not previously been available.
The aim of the current study was to examine the risk of stroke/ thromboembolism and major bleeding associated with reduced eGFR in a large Danish AF cohort and to evaluate the risk of stroke and bleeding associated with warfarin anticoagulation Background and Purpose-We sought to determine the risk of stroke/thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups. Methods-We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR. Results-A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke/thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI] , 0.97-1.56), 1.26 (95% CI, 1.14-1.40), 1.18 (95% CI, 1.07-1.31), 1.11 (95% CI, 0.87-1.42), 2.01 (95% CI, 1.14-3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m 2 , respectively. Use of warfarin was associated with lower risk of stroke/thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m ; hazard ratio 1.18 (95% CI, 0.58-2.40). Conclusions-In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function.
Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR≥15 mL/min per 1.73 m
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according to the level of renal function categorized according to eGFR. We tested the hypotheses that the risk of stroke and bleeding could be related to the level of renal function in patients with AF and that warfarin would be associated with higher risk of bleeding and lower risk of stroke independent of renal function.
Methods
Study Setting
In Denmark, every resident is provided with a unique and permanent civil registration number that allows linkage of data from several nationwide registries on an individual level. In the Danish National Patient Registry, all patients discharged from a Danish hospital are coded according to the International Classification of Disease system. 8 All invasive therapeutic procedures are coded according to the Nordic Medical Statistics Committees Classification of Surgical Procedures. All prescriptions dispensed from Danish pharmacies are registered in the Danish Registry of Medicinal Product Statistics according to the Therapeutical Chemical system. 9 The Danish Civil Registration System keeps information on vital status and cause of death for every citizen. 10 The Danish Registry on Regular Dialysis and Transplantation holds complete and valid information on all Danish citizens treated with chronic renal replacement therapy.
11
Study Population
We included all Danish residents discharged from a Danish hospital between 1997 and 2011 with a first-time primary diagnosis of AF or atrial flutter. Because information on medication relied on prescription claims and pharmacotherapy could have been changed or intensified in relation to index AF hospitalization, we began follow-up 7 days after discharge. We excluded patients who experienced major bleeding, stroke/thromboembolism, or death within the 7-day period, patients >100 or <30 years, patients with valvular AF, patients who received dabigatran, and patients who received chronic renal replacement therapy (hemodialysis, peritoneal dialysis, or kidney transplant). Patients were followed up until December 31, 2011, emigration, death, initiation of chronic renal replacement therapy, or event. All International Classification of Disease codes used to define the study population, comorbidities, and outcomes are shown in Table I in the online-only Data Supplement.
Estimating Renal Function
We identified all serum creatinine measurements available between 1996 and 2011 from hospital laboratories in 3 different counties of Denmark. Serum creatinine measurements from the General Practitioner Laboratory of Copenhagen were also included. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration formulae. 12 Baseline eGFR was estimated using the latest serum creatinine measurement up to 12 months before index AF hospitalization. For purposes of sensitivity, a mean eGFR was calculated for each patient based on all available serum creatinine measurements recorded within 12 months before index AF hospitalization. We categorized renal function as follows: eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m 2 . Renal function was determined time dependently throughout follow-up, ie, patients could switch eGFR group according to latest eGFR every time a new serum creatinine measurement was made.
Pharmacotherapy and Comorbidities
Baseline pharmacotherapy was defined using redeemed prescriptions from 180 days before discharge to 7 days hereafter. Use of warfarin was estimated time dependently throughout follow-up, as previously done, 7 by dividing the number of redeemed tablets with an estimated daily dose. Comorbidities for our population were determined as done in previous studies. 6, 7 
Study Outcomes
Outcomes under investigation were as follows: (1) death/hospitalization from stroke/thromboembolism and (2) death/hospitalization from major bleeding. Stroke/thromboembolism was defined using diagnosis codes for ischemic stroke, transient ischemic attack, or systemic thromboembolism. Major bleeding was defined using diagnosis codes denoting severe gastrointestinal, intracranial, urinary tract, and airway bleeding.
Statistics
Incidence rates of stroke/thromboembolism and major bleeding according to renal function and warfarin treatment were estimated time dependently. The Aalen-Johansen method was used to determine the cumulative incidence of stroke/thromboembolism and major bleeding, accounting for competing risk of death. As sensitivity, this was also done using (1) only creatinine measurements from general practitioners CHA 2 DS 2 -VASc indicates congestive heart failure, hypertension, age 75 years (double weight), diabetes mellitus, stroke/thromboembolism (double weight), vascular disease, age 65-74, female sex; eGFR, estimated glomerular filtration rate (mL/min per 1.73 m 2 ); HAS-BLED, hypertension, abnormal renal/liver function, previous stroke/thromboembolism, previous bleeding, labile international normalized ratio, elderly (age>75 years), alcohol abuse; IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drugs; and RASi, renin-angiotensin system inhibitors.
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Results
Characteristics of the Study Population
The selection of the study population is illustrated in Figure 1 
Follow-Up
Incidence of Stroke/Thromboembolism and Major Bleeding
Figure 2 shows 1-year cumulative incidence of stroke/ thromboembolism and major bleeding according to renal function determined at baseline. Lower eGFR was associated with greater cumulative incidence of both stroke/thromboembolism and major bleeding. Table 2 shows incidence rates of stroke/thromboembolism and major bleeding according to warfarin treatment and renal function. In patients with eGFR≥15 mL/min per 1.73 m 2 rates of stroke/thromboembolism were lower among patients who received warfarin than among patients who did not receive warfarin, and rates of major bleeding were higher among patients who received warfarin than among patients who did not receive warfarin. Patients with eGFR<15 mL/min per 1.73 m 2 had comparable rates of stroke/thromboembolism on and off warfarin and higher rates of bleeding on warfarin than off warfarin. Table 3 shows results from the multivariable adjusted Cox proportional hazard models on stroke/thromboembolism and major bleeding. A stepwise decrease in eGFR level was associated with an incremental increase in risk of stroke/thromboembolism and major bleeding when using eGFR≥90 mL/min per 1.73 m 2 as a reference. Figure 3 illustrates results from Cox proportional hazard models on stroke/thromboembolism and major bleeding associated with use of warfarin. In patients with eGFR≥15 mL/min per 1.73 m 2 , warfarin was associated with lower risk of stroke. Warfarin was associated with higher bleeding risk across eGFR groups although insignificantly in patients with eGFR≥90 mL/min per 1.73 m 2 (hazard ratio, 1.23; 95% confidence interval, 0.97-1.56) and in patients with eGFR 15 to 29 mL/min per 1.73 m 2 (hazard ratio, 1.11; 95% confidence interval, 0.87-1.42). In patients with eGFR<15 mL/min per 1.73 m 2 not receiving dialysis, warfarin was not associated with lower risk of stroke (hazard ratio, 1.18; 95% confidence interval, 0.58-1.40), but was associated with higher risk of bleeding (hazard ratio, 2.01; 95% confidence interval, 1.14-3.54). 
Sensitivity Analyses
Figures I and II in the online-only Data Supplement show cumulative incidence of stroke/thromboembolism and major bleeding by renal function determined with serum creatinine measurements obtained during index AF hospitalization. Figures III and IV in the online-only Data Supplement show cumulative incidence of stroke/thromboembolism and major bleeding by renal function as determined by using only serum creatinine measurements from general practitioners. In all analyses, Figures I through IV in the online-only Data Supplement, cumulative incidence of both stroke/thromboembolism and major bleeding were inversely correlated with eGFR. Figure V in the online-only Data Supplement shows median eGFR during the last 14 years before stroke/thromboembolism. For patients who experienced a stroke/thromboembolism, median eGFR decreased gradually during the study period, and our results were not driven by an immediate fall in eGFR before event.
Discussion
In this Danish cohort study including 17 349 AF patients with different levels of renal function, we found a stepwise higher risk of stroke/thromboembolism and major bleeding associated with decreasing levels of eGFR. Notably, the risk was higher in all patients with eGFR levels below 90 mL/min per 1.73 m 2 . Furthermore, warfarin treatment was associated with lower risk 
Risk of Stroke and Bleeding Associated With Reduced eGFR
Kidney dysfunction is associated with an increase in inflammatory and procoagulant biomarkers, including C-reactive protein, fibrinogen, factor VII, and factor VIII 13, 14 and has been considered a marker of organ damage caused by hypertension or diabetes mellitus.
2 Notably, kidney dysfunction as an independent risk factor for stroke in AF has been garnering attention, and the addition of kidney dysfunction to various stroke risk stratification tools in AF has previously been studied. 15, 16 On the contrary, kidney dysfunction is associated with hemostatic dysfunction, including decreased levels of glycoprotein IIb and IIIa, decreased activity of von Willebrand Factor and altered arachidonic acid metabolism. 17, 18 Results from other cohorts have raised safety concerns on the use of warfarin in patients with severely reduced renal function. 3 A recent cohort study by Jun et al 3 reported gradually higher crude rates of bleeding associated with reduced renal function in patients with AF who received warfarin; however, after adjustment for relevant risk factors, this association was only significant among patients with eGFR<15 mL/min per 1.73 m 2 . We found that all levels of eGFR<90 mL/min per 1.73 m 2 were associated with higher risk of stroke after adjustment for risk factors included in the CHA 2 DS 2 -VASc score. Of the 2520 patients in our study with CHA 2 DS 2 -VASc score 0 for men or 1 for women, 1541 (61.15%) had an eGFR<90 mL/ min per 1.73 m 2 at baseline and 719 (28.53%) were in treatment with warfarin. Our study was not designed or powered to investigate the net clinical benefit of warfarin in these patients, but our results suggest that the CHA 2 DS 2 -VASc score would identify more patients with AF with increased risk of stroke if reduced renal function was included.
Risks and Benefits of Warfarin Treatment in Patients With Severely Reduced Renal Function
There are no published data from randomized trials of oral anticoagulation specifically in AF patients with eGFR<30 mL/min per 1.73 m 2 , and we are aware of only a single previous observational study with available creatinine measurements that has studied the safety and efficacy of warfarin in these patients. 19 Carrero et al 19 found a lower risk of stroke/thromboembolism with warfarin in post-myocardial infarction AF patients with eGFR<15 mL/min per 1.73 m 2 . They also found lower bleeding rates on warfarin than on off warfarin, indicating possible selection bias, and the post-myocardial infarction nature of their study makes generalization to a broader AF population difficult. In the present study, warfarin treatment was associated with lower risk of stroke in all patients with eGFR>15 mL/min per 1.73 m We have previously found warfarin to be associated with lower risk of stroke, and all-cause mortality in patients with diagnosed non-end-stage chronic kidney disease and in patients on chronic renal replacement therapy. Creatinine measurements have not previously been available for our cohort, but a previous sample of 110 diagnosed patients with nonend-stage chronic kidney disease indicated that the majority of these patients (75.5%) had an eGFR>15 mL/min per 1.73 m 2 .
Patients on chronic renal replacement therapy were excluded from the present study, and these patients were younger with less comorbidity than the patients with eGFR<15 mL/min per 1.73 m 2 analyzed in this study.
Clinical Implications
Our results highlight the importance of optimal renoprotective treatment to prevent stroke/thromboembolism and bleeding 
Limitations
The study is limited by the observational design, and the small number of patients with eGFR<15 mL/min per 1.73 m 2 . We had no information on many clinical measures including international normalized ratio, body mass index, smoking status, blood pressure, hemoglobin levels, blood lipid levels, and proteinuria, and residual confounding from these or other factors cannot be excluded. Creatinine measurements were only available from 3 of 15 counties in Denmark. Thus, this reduced the number of patients available for inclusion. However, we had access to all serum creatinine measurements analyzed in the medical laboratories of these counties; hence, we have no reason to believe that this created substantial selection bias.
Conclusions
In a large Danish cohort of AF patients, risk of stroke/ thromboembolism and major bleeding were significantly associated with the level of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke/thromboembolism in patients with eGFR >15 mL/ min per 1.73 m 2 . 
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